Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Lilly

Eli Lilly Posts Stellar Q3: Long-Term Upside Is Well in Play

Eli Lilly just posted its fastest revenue growth ever, putting shares up 40% in less than three months. The stock continues to have strong long-term potential.

Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House

Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House

Eli Lilly and Company (NYSE:LLY) shares are in the spotlight following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options.

What's Up With The Rise In Eli Lilly Stock Today?

What's Up With The Rise In Eli Lilly Stock Today?

Eli Lilly and Company (NYSE:LLY) shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion for oral medicine.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

'Our GPUs Are Everywhere’ According to CEO Jensen Huang as Nvidia Doubles Down on AI, Quantum, and 6G

Nvidia stock continues to surge higher as the AI chipmaker widens its moat significantly.

Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a bidding war over the drugmaker Metsera

The Independent UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast

Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast

Eli Lilly and Co. (NYSE:LLY) on Thursday reported better-than-expected third-quarter earnings and boosted its annual forecast, sending the stock higher.

LLY Stock Update: Eli Lilly Shares Hold Firm Amid Strong Earnings

LLY Stock Update: Eli Lilly Shares Hold Firm Amid Strong Earnings

Eli Lilly and Co. (NYSE: LLY) shares are trading at $813.53 on Thursday morning, inching down 0.01% after a strong run earlier this year.

International Business Times

Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis

Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis

Eli Lilly and Co. (NYSE:LLY) on Friday shared new results from Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis.

Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections

Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections

Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM) on Friday announced that they have entered into a definitive agreement under which Lilly will acquire Adverum Biotechnologies, including its lead product, Ixo-vec.

Mounjaro Maker Eli Lilly Jumps In Quality Despite Trump-Fueled Price Cut Fears

Mounjaro Maker Eli Lilly Jumps In Quality Despite Trump-Fueled Price Cut Fears

Eli Lilly and Co. (NYSE:LLY) has surged into the top decile of quality rankings among SP 500 peers, achieving a percentile score of 90.25 on the latest composite quality report, despite fresh uncertainty surrounding the future pricing of its blockbuster weight loss drug, Mounjaro.

Trump's Weight-Loss Drug Push May Put These ETFs On A Diet

Trump's Weight-Loss Drug Push May Put These ETFs On A Diet

The weight-loss industry that fueled one of Wall Street’s most popular ETF themes may finally be going on a crash diet.

Eli Lilly Shares Are Trading Lower Friday: What's Going On?

Eli Lilly Shares Are Trading Lower Friday: What's Going On?

Eli Lilly and Company (NYSE:LLY) shares are trading lower Friday, among other GLP-1 drug manufacturers, following President Donald Trump‘s comments that fat-loss drugs will be a lot lower in price.

Get all your
news in one place.

100's of premium titles.
One news app.

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare…

The Independent UK

Warning after ‘King Kong’ of weight-loss jabs found being sold illegally on social media

Former Big Brother housemate says she thought she was ‘going to die’ after buying weight-loss jab from TikTok

Here's What to Expect From Eli Lilly’s Next Earnings Report

What should investors expect from pharma giant Eli Lilly’s upcoming Q3 results?

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead

Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments

Get all your
news in one place.

100's of premium titles.
One news app.

Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs

Eli Lilly and Co (NYSE:LLY) on Wednesday shared topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials of oral orforglipron for reducing blood sugar levels.

5 Healthcare Plays Powering the Sector’s Big Comeback

After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.

Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal

Eli Lilly just got great news, courtesy of Pfizer and Trump, leading shares to their highest level in five months. Its rally may just be getting started.

Eli Lilly Eyes India For Manufacturing, Plans To Spend $1 Billion

Eli Lilly and Co. (NASDAQ:LLY) plans to invest over $1 billion in India to strengthen its manufacturing network, according to Reuters.

Eli Lilly Shares Are Trading Higher Wednesday: What's Going On?

Eli Lilly And Company (NYSE:LLY) shares are trading higher Wednesday after President Donald Trump recently announced a deal with Pfizer as well as the ‘TrumpRx’ site to decrease prices.

Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away

Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office — it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new TrumpRx platform at steep discounts and extend "most favored nation" (MFN) pricing to Medicaid, Pfizer bought itself a…

Weight Loss Wars: Is Novo Nordisk’s Dominance Safe Against Eli Lilly?

As the battle for dominance heats up in the weight loss market, which stock is a better investment now?

1 … 3 4 5 6

People

194,182 stories

Aisleyne HorganWallace

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the White House

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

382,306 stories

Washington D.C.

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play